Analytical Data
-
Gene name
CHN2
- Application
-
Alternative Names
CHN2；ARHGAP3；BCH；Beta-chimaerin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P52757
-
Expression Region
1-468aa
-
AA Sequence
MAASSNSSLS GSSVSSDAEE YQPPIWKSYL YQLQQEAPRP KRIICPREVE NRPKYYGREF HGIISREQAD ELLGGVEGAY ILRESQRQPG CYTLALRFGN QTLNYRLFHD GKHFVGEKRF ESIHDLVTDG LITLYIETKA AEYISKMTTN PIYEHIGYAT LLREKVSRRL SRSKNEPRKT NVTHEEHTAV EKISSLVRRA ALTHNDNHFN YEKTHNFKVH TFRGPHWCEY CANFMWGLIA QGVRCSDCGL NVHKQCSKHV PNDCQPDLKR IKKVYCCDLT TLVKAHNTQR PMVVDICIRE IEARGLKSEG LYRVSGFTEH IEDVKMAFDR DGEKADISAN VYPDINIITG ALKLYFRDLP IPVITYDTYS KFIDAAKISN ADERLEAVHE VLMLLPPAHY ETLRYLMIHL KKVTMNEKDN FMNAENLGIV FGPTLMRPPE DSTLTTLHDM RYQKLIVQIL IENEDVLF
-
Molecular Weight
53.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHN2, or Chimeric Neurotrophic Factor 2, is a recombinant protein that has garnered significant interest in neurobiology and regenerative medicine due to its potential therapeutic applications in neurodegenerative diseases and nerve injury repair. Research on CHN2 began with the recognition of its structural similarities to known neurotrophic factors, which are essential for the survival, development, and function of neurons. Understanding the molecular mechanisms of CHN2 has led to insights into its ability to promote neuronal survival and regeneration. Studies have shown that CHN2 exerts neuroprotective effects by enhancing neuronal growth, inhibiting apoptosis, and modulating inflammatory responses in the nervous system. As neurodegenerative disorders such as Alzheimer's, Parkinson's, and multiple sclerosis pose major challenges in modern medicine, the exploration of CHN2 offers a promising avenue for developing novel therapeutic strategies. Furthermore, preclinical models have demonstrated CHN2’s capability to improve functional recovery following peripheral nerve injuries, highlighting its potential for clinical applications. The ongoing research aims to elucidate the precise signaling pathways involved in CHN2’s action, optimize its formulation for enhanced efficacy, and ultimately assess its safety and effectiveness in human clinical trials. Overall, the exploration of CHN2 as a recombinant protein represents a frontier in the pursuit of innovative treatments for nerve-related ailments, addressing a critical need in the field of neuroscience.
